logo-loader
viewWhitbread PLC

Whitbread shares froth higher as it agrees to sell Costa coffee to Coca-Cola for £3.9bn

The company said it plans to return a “significant majority” of proceeds from the disposal to shareholders

Costa
The deal is expected to be completed in the first half of 2019

Whitbread PLC (LON:WTB) shares frothed up more than 16% after saying it has agreed to sell its Costa coffee chain to The Coca-Cola Co. (NYSE:KO) for £3.9bn.

The group, which also owns the Premier Inn hotel chain, announced plans in April to split off Costa into a separate entity after receiving pressure from activist investors Elliott Advisors and Sachem Head.

Whitbread chief executive Alison Brittain said the deal with Coca-Cola “represents a substantial premium to the value that would have been created through the demerger of the business and we expect to return a significant majority of net proceeds to shareholders”.

READ: Whitbread shares fall as it confirms spin off of Costa Coffee after activist investor pressure

The deal representing a multiple of 16.4x Costa’s fiscal year 2019 earnings (EBITDA).

Whitbread to use proceeds for shareholder returns, cutting debt 

The company said it plans to return a “significant majority” of proceeds from the disposal to shareholders. Net cash proceeds are estimated to be £3.8bn after transaction and separation costs.

It will also use some of the proceeds to reduce debt and to fund its pension scheme, providing extra headroom for the expansion of Premier Inn in the UK and Germany.

The deal is expected to be completed in the first half of 2019, subject to shareholder and regulatory approvals.

Coca-Cola president and chief executive, James Quincey, said: “Hot beverages is one of the few remaining segments of the total beverage landscape where Coca-Cola does not have a global brand. Costa gives us access to this market through a strong coffee platform. I'd like to welcome the team to Coca-Cola and look forward to working with them."

Whitbread bought Costa for £19mln in 1995 when the business had just 39 outlets. It is now the UK's largest coffee chain with more than 2,400 UK coffee shops and 1,400 outlets in 31 overseas markets. Costa Express has 8,237 vending machines across the globe.

In morning trading, shares in Whitbread were up 16.2% to 4,670p each.

Deal represents rich valuation but Whitbread is losing jewel in its crown, says analyst

"On the one hand £3.9 billion is an undeniably rich valuation and likely far better than Costa could achieve as an independently listed company, valuing its earnings higher than those of the mighty Starbucks," said Nicholas Hyett, equity analyst at Hargreaves Lansdown.

"On the other, Costa has long been the jewel in Whitbread’s crown and some will be sad to see it go at any price, especially given the growth potential in China and elsewhere."

Hyett said Coca-Cola's global reach should turbo-charge growth in the years to come and hot drinks is one of the few areas in beverages where the soft drinks giant doesn’t have a major brand.

On the remaining business, Premier Inn, Hyett said:  "Progress has been good and we believe the product is excellent, but it’s a very different business to Costa and growth will be slower and demand more up-front investment."

He added: "An excellent deal it may be, but Whitbread investors may miss the caffeine highs Costa serves up."

Quick facts: Whitbread PLC

Price: 4219 GBX

LSE:WTB
Market: LSE
Market Cap: £5.64 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Morning Report: Faron Pharma expands MATINS trial to include ovarian cancer

Headlines from the Proactive UK newsroom. Faron Pharmaceuticals (LON:FARN) is to expand its phase I/II MATINS clinical trial of its Clevegen cancer drug to women with ovarian cancer. Earlier this month, Faron was also given permission to expand the ongoing trial into late-stage colorectal...

2 hours, 59 minutes ago

RNS

Director/PDMR Shareholding

3 hours, 38 minutes ago

Block listing Interim Review

3 hours, 39 minutes ago

Director/PDMR Shareholding

1 week, 4 days ago

Q3 FY20 Trading Update

1 week, 4 days ago

Total Voting Rights

3 weeks, 4 days ago

3 min read